Anti-CD38 mAbs, such as daratumumab and isatuximab, induce MM cell death through CD38 binding; this CD38-mediated ADCC also results in the elimination of CD38+ NK cells (NK cell fratricide) [72, 90] by leaving an activated CD38low/− NK cell population. This evidence concerns the gene CD38 and Miyoshi myopathy.